Ethical considerations in industry-sponsored Multiregional Clinical Trials

被引:7
|
作者
Ibia, Ekopimo [1 ]
Binkowitz, Bruce [1 ]
Saillot, Jean-Louis [1 ]
Talerico, Steven [1 ]
Koerner, Chin [2 ]
Ferreira, Irene [3 ]
Agarwal, Anupam [4 ]
Metz, Craig [4 ]
Maman, Marianne [2 ]
机构
[1] Merck & Co Inc, Whitehouse Stn, NJ USA
[2] Novartis Pharmaceut, Rockville, MD USA
[3] Amgen Inc, Cambridge, Cambs, England
[4] GlaxoSmithKline Plc, Collegeville, PA USA
关键词
ethical principles; Multiregional Clinical Trials; global trials; post-trial benefits; informed consent process; data monitoring; DEVELOPING-COUNTRIES; GLOBALIZATION;
D O I
10.1002/pst.458
中图分类号
R9 [药学];
学科分类号
1007 ;
摘要
During the last several decades, the scientific and ethics communities have addressed important ethical issues in medical research, resulting in the elaboration and adoption of concepts, guidelines, and codes. Ethical issues in the conduct of Multiregional Clinical Trials have attracted significant attention mainly in the last two decades. With the globalization of clinical research and the rapid expansion to countries with a limited tradition of biomedical research, sponsors must proactively address local ethical issues, the adequacy of oversight as well as the applicability and validity of data, and scientific conclusions drawn from diverse patient populations. This paper highlights some core ethical principles and milestones in medical research, and, from an industry perspective, it discusses ethical issues that the clinical trial team may face when conducting Multiregional Clinical Trials (MRCT, clinical trials conducted at sites located across multiple geographic regions of the world). This paper further highlights the areas of consensus and controversies and proposes points to consider. Copyright (C) 2010 John Wiley & Sons, Ltd.
引用
收藏
页码:230 / 241
页数:12
相关论文
共 50 条
  • [41] Uniform guidelines for reporting COI within industry-sponsored clinical trials (ISCT)
    Hussey, Valerie
    [J]. MULTIPLE SCLEROSIS JOURNAL, 2015, 21 (12) : 1496 - 1497
  • [42] Industry-Sponsored Research in Plastic Surgery: Implications and Considerations
    Travieso, Roberto
    Patel, Anup
    Au, Alexander F.
    [J]. PLASTIC AND RECONSTRUCTIVE SURGERY, 2014, 134 (05) : 858E - 859E
  • [43] Forewarned is forearmed: Trends in industry-sponsored clinical trials relevant to publication professionals
    Anderson, Michelle F.
    Hisayama, Masayo
    Deckman, Jessica
    Haley, Cassandra
    Traynor, Russell
    Woolley, Karen L.
    [J]. CURRENT MEDICAL RESEARCH AND OPINION, 2016, 32 : S9 - S9
  • [44] Industry-Sponsored Clinical Trials in Emerging Markets Time to Review the Terms of Engagement
    MacMahon, Stephen
    Perkovic, Vlado
    Patel, Anushka
    [J]. JAMA-JOURNAL OF THE AMERICAN MEDICAL ASSOCIATION, 2013, 310 (09): : 907 - 908
  • [45] CONFLICT-OF-INTEREST AND INFORMED CONSENT IN INDUSTRY-SPONSORED CLINICAL-TRIALS
    SHIMM, DS
    SPECE, RG
    [J]. JOURNAL OF LEGAL MEDICINE, 1991, 12 (04) : 477 - 513
  • [46] PREVALENCE OF GHOST-AUTHORSHIP IN INDUSTRY-SPONSORED IBD BIOLOGIC CLINICAL TRIALS
    Li, Juana
    Hu, Malini
    Scaffidi, Michael A.
    Gimpaya, Nikko
    Bansal, Rishi
    Verma, Yash
    Elsolh, Karam
    Khan, Rishad
    Grover, Samir C.
    [J]. GASTROENTEROLOGY, 2021, 160 (06) : S212 - S212
  • [47] NEW DRUGS FOR PERINATAL PRACTICE - THE ROLE OF INDUSTRY-SPONSORED CLINICAL-TRIALS
    LONG, W
    ZENG, GB
    HENRY, GW
    [J]. SEMINARS IN PERINATOLOGY, 1995, 19 (02) : 132 - 143
  • [48] Counterpoint: Were Industry-Sponsored Roflumilast Trials Appropriate? No
    Rho, Jason
    Ho, Nancy
    Prasad, Vinay
    [J]. CHEST, 2014, 145 (05) : 939 - 942
  • [49] Industry-sponsored clinical research - A broken system
    Angell, Marcia
    [J]. JAMA-JOURNAL OF THE AMERICAN MEDICAL ASSOCIATION, 2008, 300 (09): : 1069 - 1071
  • [50] Industry-sponsored research
    Blumenthal, HJ
    [J]. HEADACHE, 2004, 44 (02): : 191 - 191